Brian Lian, President and CEO, reported that "the Viking team continued to focus on execution of our core clinical strategy," emphasizing advancement of both oral and subcutaneous VK2735 programs. "We ...
SAN DIEGO, Oct. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...
Lian said the company expects to announce Phase II oral VK2735 results later in the year and is planning to evaluate a monthly dosing regimen for VK2735 in the maintenance setting later this year. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results